RxDoctor Payments Data

Bradley Copple, DPM

Foot & Ankle Surgery · Omaha, NENPI 1962648410

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (49.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Organogenesis Inc. accounts for 75.8% of it on its own, with 20 other manufacturers making up the rest. Among foot & ankle surgery clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$82,775in general payments, 2019–2025

Across 280 payments — averaging $295.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organogenesis Inc.$63K
  • Stryker$7K
  • Acera Surgical, Inc.$6K
  • Arthrex$4K
  • Integra Lifesciences Corporation$998
  • Conetic Solutions, Inc.$557
  • plus $1K from 15 others
$50,000in ownership & investment interests, 2019–2025

Across 6 payments — averaging $8333.33 each. An ownership or investment interest held by the physician or an immediate family member.

  • Gramercy Extremity Orthopedics LLC$50K

What the payments were for

  • Consulting fees$21,76026%
  • Speaking & faculty fees$40,56449%
  • Travel & lodging$8,77211%
  • Food & beverage$8,28010%
  • Education$2,6933%
  • Other$7071%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$82,775 in reported general payments places this provider in the 95th percentile of 43 foot & ankle surgery providers in Nebraska.

See all foot & ankle surgery providers in Nebraska

Medicare billing

Part B allowed, 2024
$551,699
Medicare patients
280
Services billed
1,089

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip43$1,167
Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort12$619
Doxycycline Hyclate33$297
Cephalexin11$81
Meloxicam19$55

Paid to pharmacies, not to this prescriber.

Other foot & ankle surgery in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →